학술논문
De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial
Document Type
Article
Author
Source
In The Lancet Haematology July 2019 6(7):e375-e383
Subject
Language
ISSN
2352-3026